New Targets in the Crosshairs: A forum to invalidate patents is now being used on biotech firms

June 2015

Since they first became available in September 2012, inter partes review proceedings continue to gain popularity as a means of challenging the validity of patents. While IPRs have had the most impact on patents in the electrical and computer fields, their influence on biotechnology patents is on the rise. IPR petitions challenging biotech/pharma patents in fiscal 2015 have more than tripled from the same period last year. In fact, there have been more IPR petitions in fiscal 2015 for biotech/pharma patents (73 as of March 26) than the combined total from September 2012 through April 2014 (59 as of April 10, 2014).

To continue reading Irena Royzman and Zhiqiang Liu's article from the June 2015 edition of Corporate Counsel magazine, please click here.